Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.85 EUR | -1.25% | +0.87% | -6.45% |
06:13am | Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India | MT |
05-14 | BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.45% | 18.23B | - | ||
+9.58% | 115B | B+ | ||
+12.41% | 107B | B+ | ||
-2.59% | 21.6B | B | ||
-12.38% | 22.31B | B+ | ||
-5.29% | 19.19B | A- | ||
-38.57% | 17.62B | A- | ||
+7.51% | 14.26B | C+ | ||
+35.67% | 12.37B | C+ | ||
-24.50% | 8.28B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BGNE Stock
- 49B Stock
- Ratings BeiGene, Ltd.